{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:35:15Z","timestamp":1740155715047,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T00:00:00Z","timestamp":1421712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/nrneph.2014.252","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T11:17:06Z","timestamp":1421752626000},"page":"205-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["New nonabsorbable potassium-exchange resins in hyperkalaemia"],"prefix":"10.1038","volume":"11","author":[{"given":"Sara S.","family":"Roscioni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiddo J. Lambers","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,20]]},"reference":[{"key":"BFnrneph2014252_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrneph.2012.217","volume":"8","author":"SS Roscioni","year":"2012","unstructured":"Roscioni, S. S., de Zeeuw, D., Bakker, S. J. & Lambers Heerspink, H. J. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat. Rev. Nephrol. 8, 691\u2013699 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2014252_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1681\/ASN.2010010079","volume":"5","author":"RH Sterns","year":"2010","unstructured":"Sterns, R. H., Rojas, M., Bernstein, P. & Chennupati, S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J. Am. Soc. Nephrol. 5, 733\u2013735 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2014252_CR3","doi-asserted-by":"publisher","unstructured":"Weir, M. R.  et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N. Engl. J. Med. \n                    http:\/\/dx.doi.org\/10.1056\/NEJMoa1410853\n                    \n                  .","DOI":"10.1056\/NEJMoa1410853"},{"key":"BFnrneph2014252_CR4","doi-asserted-by":"publisher","unstructured":"Packham, D. K.  et al. Sodium zirconium cyclosilicate in hyperkalemia. N. Engl. J. Med. \n                    http:\/\/dx.doi.org\/10.1056\/NEJMoa1411487\n                    \n                  .","DOI":"10.1056\/NEJMoa1411487"},{"key":"BFnrneph2014252_CR5","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod, M.  et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312, 2223\u20132233 (2014).","journal-title":"JAMA"},{"key":"BFnrneph2014252_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf, S.  et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547\u20131559 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2014252_CR7","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving, H. H.  et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204\u20132213 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2014252_CR8","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried, L. F.  et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 369, 1892\u20131903 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2014252_CR9","first-page":"299","volume":"3","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink, H. J.  et al. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur. J. Prev. Cardiol. 3, 299\u2013309 (2013).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"BFnrneph2014252_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","volume":"54","author":"Y Miao","year":"2011","unstructured":"Miao, Y.  et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 54, 44\u201350 (2011).","journal-title":"Diabetologia"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.252","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:44:36Z","timestamp":1684471476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2014.252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,20]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFnrneph2014252"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2014.252","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"type":"print","value":"1759-5061"},{"type":"electronic","value":"1759-507X"}],"subject":[],"published":{"date-parts":[[2015,1,20]]},"assertion":[{"value":"20 January 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2015","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of this article that was initially published online, the withdrawal phase of the study by Weir <i>et al<\/i>. was incorrectly described as double-blind rather than single-blind and ZS-9 was incorrectly described as a nonabsorbable polymer rather than a high-specificity inorganic crystal. The errors have been corrected in the html and pdf versions of the article.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.J.L.H. is a consultant for and has received honoraria (paid to his employer) from AbbVie, Astellas, Johnson & Johnson and Reata. S.S.R. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}